| 摘要 |
A method of inducing tolerance to a therapeutic cell in a patient who is to be administered subsequently a therapeutic amount of the said therapeutic cell or a precursor thereof, the method comprising administering to the patient (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell, or an antigen found thereon or a derivative of said antigen, and (b) an agent which raises the effective cAMP concentration in a monocyte cell. A method of reducing the risk of rejection of a transplant in a patient in need of transplantation of a therapeutic cell for cell or tissue regeneration, the method comprising administering to the patient prior to the transplant (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell which therapeutic cell is, or is able to differentiate into, the cell or tissue to be regenerated, or an antigen found thereon or a derivative of said antigen, and (b) an agent which raises the effective cAMP concentration in a monocyte cell. A method of treating a patient in need of cell or tissue regeneration the method comprising administering to the patient (a) a tolerising cell sharing the same antigenic characteristics as the therapeutic cell to be administered subsequently which therapeutic cell is, or is able to differentiate into, the cell or tissue to be regenerated, or an antigen found thereon or a derivative of said antigen, (b) an agent which raises the effective cAMP concentration in a monocyte cell in an amount to induce tolerance to the said therapeutic cell, and subsequently administering to the patient (c) a therapeutic amount of the said therapeutic cell. Preferably, the agent which raises the effective cAMP concentration in a monocyte cell is a prostaglandin. Preferably it is used in combination with GMCSF or a derivative thereof.
|
